OncoResponse: OncoResponse: $13 Million Grant And $14 Million In Funding Received

OncoResponse - a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders - announced it has been awarded a $13 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The post OncoResponse: $13 Million Grant And $14 Million In Funding Received appeared first on Pulse 2.0.